StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research note published on Sunday morning. The firm issued a sell rating on the stock.

Separately, Piper Sandler reaffirmed an “overweight” rating and set a $4.50 price target on shares of InspireMD in a research note on Tuesday, September 17th.

InspireMD Stock Up 4.0 %

InspireMD stock opened at $2.48 on Friday. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.42. The stock has a market cap of $61.83 million, a P/E ratio of -3.31 and a beta of 0.93. The company’s fifty day simple moving average is $2.59 and its 200-day simple moving average is $2.58.

Institutional Trading of InspireMD

An institutional investor recently bought a new position in InspireMD stock. Affiance Financial LLC bought a new stake in InspireMD, Inc. (NYSE:NSPR) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned about 0.74% of InspireMD as of its most recent SEC filing. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.